This post was originally published on this site Advaxis and Bristol-Myers Squibb have entered a clinical collaboration to evaluate the second generation of axalimogene filolisbac, called ADXS-DUAL, in combination with Opdivo (nivolumab) in women with metastatic cervical cancer. In particular, the study will assess the combination in patients with persistent, recurrent or metastatic (squamous or…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Keytruda Shows Promise in People with Advanced Disease, Early Phase 2 Trial Results Show
This post was originally published on this site Merck’s Keytruda (pembrolizumab) shows promise as a treatment for advanced, previously treated cervical squamous cell cancer, according to a preliminary analysis of a Phase 2 trial. The data, which will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, indicated response…
Chemotherapy Plus P53 Gene Therapy May Help Treat Locally Advanced Cervical Cancer
This post was originally published on this site Locally advanced cervical cancer (LACC) may be treated with a combination of neoadjuvant chemotherapy (administered before surgery) and p53 gene therapy, according to a new clinical trial. The trial results, titled “Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial,”…
Cervical Cancer Screening Device Mía, by Mel-Mont Medical, Allows HPV Sampling at Home
This post was originally published on this site A new diagnostic system by Mel-Mont Medical that allows women to collect cervical cell samples at home could help boost cervical cancer screening in areas where women lack access to health services. This could help prevent unnecessary deaths caused by this preventable disease, the company said. The system, called Mía…
Cervical Cancer Patient Achieves Long-lasting Response to AXAL in Clinical Trial
This post was originally published on this site One of nine cervical cancer patients treated with AXAL achieved a long-lasting partial response to the therapy, according to a Phase 1 study. The treatment’s maker, Advaxis, presented the results in a poster session at a National Cancer Research Institute conference in Liverpool, England. The trial covered patients with persistent or…
Synthetic Genomics, Advaxis Launch Venture to Produce Synthetic DNA for Immunotherapy Clinical Trials
This post was originally published on this site Synthetic Genomics and Advaxis have developed a current good manufacturing practice (cGMP) synthetic biology suite to produce synthetic DNA constructs. The cGMP facility meets U.S. Food and Drug Administration (FDA) requirements to begin a Phase 1 clinical trial testing ADXS-NEO — a potential immunotherapy made by Advaxis to treat a…
S-1 and Platinol Combo Shows Promise Against Cervical Cancer, Phase 3 Trial Indicates
This post was originally published on this site Adding S-1 to Platinol (cisplatin) chemotherapy improved cervical cancer patients’ response to treatment and lengthened the time it took for their disease to progress, according to a Phase 3 clinical trial. Taiho Pharmaceutical, which developed S-1, presented the results at the American Society of Clinical Oncology annual meeting in…
Opdivo Showing Early Promise in Advanced Cervical Cancer Patients Enrolled in Phase 1/2 Trial
This post was originally published on this site Preliminary data from a Phase 1/2 trial, presented at the American Society of Clinical Oncology Annual 2017 Annual Meeting, shows that Opdivo (nivolumab) monotherapy was effective in more than 26 percent of patients with cervical cancer, regardless of their PD-L1 or HPV status, or number of prior…